Kiniksa Pharmaceuticals International (KNSA) Stock Price, News & Analysis

Company Overview

Kiniksa Pharmaceuticals International, Ltd. is a biopharmaceutical company focused on developing and commercializing therapies for patients with debilitating diseases, including conditions driven by immune-system and inflammatory responses. The company’s strategy centers on targeted medicines intended to address significant unmet medical needs in specialty markets.

Kiniksa’s primary commercial product is ARCALYST (rilonacept), an interleukin-1 blocker. In the United States, ARCALYST is approved for the treatment of recurrent pericarditis and for reducing the risk of recurrence in adults and children age 12 and older. It is also approved for the treatment of cryopyrin-associated periodic syndromes, a group of rare autoinflammatory disorders.

Kiniksa was founded in 2015 and operates as part of the broader Kiniksa Pharmaceuticals organization, which is headquartered in Bermuda with operations in the United States. Sanj K. Patel is the company’s co-founder, chairman and chief executive officer. The company’s commercial activities are primarily focused on specialty and rare-disease markets, supported by research and development programs in immunology and inflammation.

Key Stats

• Today's Range: $79.62 to $82.98
• 50-Day Range: $74.61 to $80.80
• 52-Week Range: $35.20 to $82.98
• Volume: 1.48 million shs
• Average Volume: 536,731 shs
• Market Capitalization: $6.24 billion
• P/E Ratio: 82.41
• Dividend Yield: N/A
• Price Target: $93.14
• Consensus Rating: Moderate Buy

Kiniksa Pharmaceuticals International Stock Analysis - MarketRank™

Kiniksa Pharmaceuticals International scored higher than 81% of companies evaluated by MarketBeat, and ranked 110th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Kiniksa Pharmaceuticals International has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on no strong buy ratings, 8 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Kiniksa Pharmaceuticals International has a consensus price target of $93.14, representing about 16.5% upside from its current price of $79.94.

Amount of Analyst Coverage

Kiniksa Pharmaceuticals International has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 51.09%

Earnings Growth

Earnings for Kiniksa Pharmaceuticals International are expected to grow by 51.09% in the coming year, from $1.37 to $2.07 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Kiniksa Pharmaceuticals International is 82.41, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 36.01.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kiniksa Pharmaceuticals International is 82.41, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 209.00.

Price to Book Value per Share Ratio

Kiniksa Pharmaceuticals International has a P/B Ratio of 10.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.09% of the float of Kiniksa Pharmaceuticals International has been sold short.

Short Interest Ratio / Days to Cover

Kiniksa Pharmaceuticals International has a short interest ratio ("days to cover") of 6.41.

Change versus previous month

Short interest in Kiniksa Pharmaceuticals International has recently decreased by 2.53%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kiniksa Pharmaceuticals International does not currently pay a dividend.

Dividend Growth

Kiniksa Pharmaceuticals International does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.91

News Sentiment

Kiniksa Pharmaceuticals International has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Kiniksa Pharmaceuticals International this week, compared to 3 articles on an average week.

Search Interest

Only 3 people have searched for KNSA on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

MarketBeat Follows

5 people have added Kiniksa Pharmaceuticals International to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Kiniksa Pharmaceuticals International insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $668,472.00 in company stock.

Percentage Held by Insiders

51.98% of the stock of Kiniksa Pharmaceuticals International is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

53.95% of the stock of Kiniksa Pharmaceuticals International is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/28/2026
• Today: 10/16/2026
• Next Earnings (Estimated): 10/27/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:KNSA
• CIK: 1730430
• Web: www.kiniksa.com
• Phone: (781) 431-9100
• Fax: N/A
• Employees: 366
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Kiniksa Pharmaceuticals International: $93.14
• High Price Target: $107.00
• Low Price Target: $71.00
• Potential Upside/Downside: +16.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.89
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.97
• Trailing P/E Ratio: 82.41
• Forward P/E Ratio: 58.35
• P/E Growth: N/A
• Net Income: $59.01 million
• Net Margins: 9.59%
• Pretax Margin: 13.59%
• Return on Equity: 13.65%
• Return on Assets: 10.09%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.90
• Quick Ratio: 3.49

Sales & Book Value

• Annual Sales: $677.56 million
• Price / Sales: 9.20
• Cash Flow: $0.80 per share
• Price / Cash Flow: 99.32
• Book Value: $7.44 per share
• Price / Book: 10.74

Miscellaneous

• Outstanding Shares: 78,020,000
• Free Float: 37,467,000
• Market Cap: $6.24 billion
• Optionable: Optionable
• Beta: 0.04